Literature DB >> 23634371

Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease.

Howard D Weiss1, Laura Marsh.   

Abstract

Impulse control disorders (ICD) (most commonly pathologic gambling, hypersexuality, and uncontrollable spending) and compulsive behaviors can be triggered by dopaminergic therapies in Parkinson disease (PD). ICD are especially prevalent in patients receiving a dopamine agonist as part of their treatment regimen for PD, and have also been reported when dopamine agonists are used for other indications (e.g., restless legs syndrome). Although these iatrogenic disorders are common, affecting 1 in 7 patients with PD on dopamine agonists, they often elude detection by the treating physician. ICD lead to serious consequences, causing significant financial loss and psychosocial morbidity for many patients and families. ICD can appear at any time during treatment with dopamine agonists, sometimes within the first few months, but most often after years of treatment, particularly when patients receive dopamine agonists and levodopa together. In most cases ICD resolve if the dopamine agonist is withdrawn, and PD motor symptoms are managed with levodopa monotherapy. Familiarity with the clinical aspects, risk factors, pathophysiology, and management of ICD is essential for physicians using dopaminergic therapies to treat PD and other disorders.

Entities:  

Year:  2012        PMID: 23634371      PMCID: PMC3613210          DOI: 10.1212/CPJ.0b013e318278be9b

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  10 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Detection of impulse control disorders in Parkinson disease patients.

Authors:  Howard D Weiss; Elaina S Hirsch; James R Williams; Leah Swearengin; Laura Marsh
Journal:  Neurologist       Date:  2010-11       Impact factor: 1.398

3.  Long-term follow-up of impulse control disorders in Parkinson's disease.

Authors:  Eugenia Mamikonyan; Andrew D Siderowf; John E Duda; Marc N Potenza; Stacy Horn; Matthew B Stern; Daniel Weintraub
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 4.  Medication-related impulse control and repetitive behaviors in Parkinson disease.

Authors:  Valerie Voon; Susan H Fox
Journal:  Arch Neurol       Date:  2007-08

5.  Clinical features associated with impulse control disorders in Parkinson disease.

Authors:  Gregory Pontone; James R Williams; Susan Spear Bassett; Laur Marsh
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

6.  Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Authors:  Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

Review 7.  Impulse control disorders and pathological gambling in patients with Parkinson disease.

Authors:  William Stamey; Joseph Jankovic
Journal:  Neurologist       Date:  2008-03       Impact factor: 1.398

8.  Dopamine agonist withdrawal syndrome in Parkinson disease.

Authors:  Christina A Rabinak; Melissa J Nirenberg
Journal:  Arch Neurol       Date:  2010-01

9.  Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.

Authors:  J Michael Bostwick; Kathleen A Hecksel; Susanna R Stevens; James H Bower; J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

Review 10.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  Andrew H Evans; Antonio P Strafella; Daniel Weintraub; Mark Stacy
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

  10 in total
  17 in total

1.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

2.  Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.

Authors:  Federica Bono; Paola Savoia; Adele Guglielmi; Massimo Gennarelli; Giovanna Piovani; Sandra Sigala; Damiana Leo; Stefano Espinoza; Raul R Gainetdinov; Paola Devoto; PierFranco Spano; Cristina Missale; Chiara Fiorentini
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

3.  Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2017-06

4.  Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.

Authors:  Bruno Fukelmann Guedes; Marcia Rubia Gonçalves; Rubens Gisbert Cury
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

Review 5.  Treating prolactinomas with dopamine agonists: always worth the gamble?

Authors:  Sean Noronha; Victoria Stokes; Niki Karavitaki; Ashley Grossman
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

Review 6.  "Pseudo-syndromes" associated with Parkinson disease, dementia, apathy, anxiety, and depression.

Authors:  Howard D Weiss; Gregory M Pontone
Journal:  Neurol Clin Pract       Date:  2019-08

Review 7.  Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review.

Authors:  Domenico Pirritano; Massimiliano Plastino; Domenico Bosco; Luca Gallelli; Antonio Siniscalchi; Giovambattista De Sarro
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

8.  Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease.

Authors:  Masoud Tahmasian; Luisa Rochhausen; Franziska Maier; Kim L Williamson; Alexander Drzezga; Lars Timmermann; Thilo Van Eimeren; Carsten Eggers
Journal:  Front Behav Neurosci       Date:  2015-11-30       Impact factor: 3.558

9.  Impulse-Control Disorders in Parkinson's Disease: A Meta-Analysis and Review of Case-Control Studies.

Authors:  Helge Molde; Yasaman Moussavi; Stine Therese Kopperud; Aleksander Hagen Erga; Anita Lill Hansen; Ståle Pallesen
Journal:  Front Neurol       Date:  2018-05-22       Impact factor: 4.003

Review 10.  Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.

Authors:  Hammad Ullah; Haroon Khan
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.